GlassScriptPhysician profile
Melanie Moore
NPI 1861024606
$5,693.31
in general payments reported to CMS, 2019-2025
24 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,204 · 2022: $942 · 2023: $791 · 2024: $370 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $995.68 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $653.43 | 2021-2022 | |
| Abbvie INC. | $631.37 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $450.34 | 2021-2023 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $358.58 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $347.46 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $341.98 | 2021 | |
| Axsome Therapeutics, INC. | $274.57 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $251.14 | 2021-2023 | Spravato |
| Supernus Pharmaceuticals, INC. | $206.62 | 2021-2023 | Qelbree |
| Lundbeck LLC | $206.48 | 2021-2023 | Rexulti |
| Tris Pharma INC | $171.32 | 2021 | |
| Neurocrine Biosciences, INC. | $136.88 | 2022 | |
| Corium, LLC | $127.81 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $124.98 | 2025 | Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $108.33 | 2022-2023 | Jornay Pm |
| Almatica Pharma LLC | $78.77 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Validus Pharmaceuticals LLC | $75.73 | 2022-2023 | Equetro |
| Bausch Health US, LLC | $40.67 | 2022-2023 | Aplenzin |
| Harmony Biosciences LLC | $34.68 | 2021 | |
| Biogen, INC. | $25.94 | 2021 | |
| Tempus Ai, INC | $21.32 | 2024 | |
| Noven Therapeutics, LLC | $14.62 | 2024 | Xelstrym |
| Alfasigma USA, INC. | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.